EMTRICITABINE/TENOFOVIR DISOPROXIL KRKA D.D. 200 mg/245 mg, film-coated tablet 28 tablets
Active ingredients: Emtricitabine, Tenofovir disoproxil succinate, Tenofovir disoproxil
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- EMTRICITABINE/TENOFOVIR DISOPROXIL KRKA D.D. 200 mg/245 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium polyéthylène de 28 comprimé(s)
- Marketing authorisation holder
- KRKA (SLOVENIE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 6 Dec 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62778588CIP73010088CIP133400930100882Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TÉNOFOVIR DISOPROXILcomprimé | 245 mg · un comprimé | FT |
| SUCCINATE DE TÉNOFOVIR DISOPROXILcomprimé | 300,70 mg · un comprimé | SA |
| EMTRICITABINEcomprimé | 200 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.